SPECIFICALLY, BIOMARKERS FOR PREDICTING BIPOLAR DISORDER

Authors: Dr.Yadala Prapurna Chandra Ph.D[1]*, Kongi Kavyasudha M.Pham P.Cology[2], Gorusetty Aswini[3]

[1*] Principal of Rathnam Institute of Pharmacy, Pidathapolur, Nellore. Ph.D. in Pharmacology, KLE University, Belgaum.
[2] Faculty- Associate Professor of Pharmacology, Rathnam Institute of Pharmacy, Pidathapolur, Nellore. M.Pharm. in Pharmacology, Sree Venkateshwara University, Tirupati.
[3] Pursuing Bachelor of Pharmacy at Rathnam Institute of Pharmacy, Pidathapolur, Nellore.

ABSTRACT:

Bipolar disorder (BD) is a complex mental health condition characterized by significant mood fluctuations, leading to substantial psychosocial impairment and increased mortality rates. The differentiation between BD and depression is crucial, as early recognition of BD can mitigate adverse outcomes. Recent studies utilizing artificial intelligence have attempted to predict the transition from depression to BD, yet challenges remain in achieving reliable external validation. The prevalence of mood disorders has surged, particularly following the COVID-19 pandemic, necessitating accurate diagnostic tools and treatment strategies. Biomarkers, including neuroimaging, peripheral, and genetic markers, hold promise for enhancing the understanding and management of BD. These biomarkers can aid in diagnosis, monitor treatment responses, and potentially guide personalized therapeutic approaches. Current treatment options encompass psychotherapeutic interventions, pharmacological therapies, and lifestyle modifications. Despite advancements, the field faces challenges in biomarker discovery, requiring a shift from traditional reductionist methods to more integrative approaches. Future research should focus on identifying robust biomarkers that can facilitate early diagnosis and tailored treatment for individuals with BD.

KEYWORDS: Bipolar disorder, biomarkers, artificial intelligence, mood disorders, treatment strategies, diagnosis.

INTRODUCTION:

Mood disorders such as depression and bipolar disorder (BD) fundamentally cause handicap that seriously restricts individual psychosocial works and brings down the personal satisfaction. BD has a less positive visualization and necessities medicines not quite the same as those required for sadness, albeit both have covering side effects and pathophysiology. Brief acknowledgment of despondency transformation to BD might assist with forestalling the unfortunate results of BD since BD is at first mistaken for gloom. Be that as it may, early BD acknowledgment or expectation among individuals with sadness is trying because of deferred symptomatic separation [1].

A few AI studies have been led to foresee the demonstrative change from melancholy to BD. One review created models with a region under the bend (AUC) of 0.76. Nonetheless, the model was created utilizing a solitary place, and the exhibition disintegrated to ≤0.71 in outer approval. Nestsiarovich et al fostered a forecast model of the transformation from sadness to BD across numerous data sets in the US. That model had terrible showing during outer approval and its general presentation was unobtrusive. Further, that study was led utilizing information centralization, which can't be all around embraced in numerous charitable foundations because of protection and administrative worries, particularly in exceptionally delicate fields like psychiatry [2].

Wellbeing limitations are as of now causing attacks in the field of psychiatry, with a blast of uneasiness and melancholy issues. To be sure, ongoing examinations exhibit an enormous increment of gloom commonness since Coronavirus pandemic. Besides, the spread of Coronavirus and significant passing rate might bother the gamble of emotional well-being issues and heighten current mental side effects of specific people who

are on chance of tension, sorrow, stress, and brutality. In this manner, the requirement for a dependable and precise differential conclusion, permitting a sufficient treatment, of these pathologies has turned into a vital need for the next few years [3].

BIPOLAR DISORDER :

Bipolar disorder (BD) is a persistent mental problem set apart by clinical and pathophysiological heterogeneity. There is an exclusive requirement that customized approaches can work on the administration of patients with BD. For that, distinguishing proof and approval of potential biomarkers are crucial [4].

Bipolar turmoil (BD) is an extreme intermittent temperament problem, related with a critical dismalness and mortality, with high paces of suicides and clinical comorbidities. The survey presents a basic an and update on probably the most encouraging possibility for biomarkers, in particular, neuroimaging markers ,fringe biomarkers and hereditary markers , remembering a concise conversation for end aggregate as demonstrative of hereditary gamble. The examples gained from different fields and strengths in medication should be applied to psychiatry to decipher the information from 'seat to bedside' through clinically valuable biomarkers. Generally the biomarkers might help in pushing the shift towards customized medication for mental patients [5].

BD influences 1-2 percent of everybody , with predominance rates coming to as high as 4-5 percent for the bipolar range problems. Almost seven percent of the weight owing to mental and conduct problems [as estimated by inability - changed life years [DALY] is contributed by BD. It is related with a huge mortality , with high paces of suicides and clinical comorbidities (for example cardiovascular sicknesses). There is high gamble of creating state of mind problems among the organic family members of patients with BD, showing major areas of strength for a part [6].

Some of ways biomarkers are use in bipolar disorder:

Biomarkers give a likely objective to distinguishing indicators of reaction to different interventions.The proof to date proposes that markers mirroring the action of fiery, synapse, neurotrophic, neuroendocrine and metabolic frameworks might have the option to foresee mental and actual wellbeing results in presently discouraged people, yet there is a lot of irregularity between findings. In this survey, we center around these five biologic frameworks [7].

Diagnostic biomarker:

Incorporates an assortment of biomarkers used to recognize or affirm the presence of an illness or ailment. This sort of biomarker can be utilized to recognize illness subtypes. The coming of the period of the accuracy medication stresses the way that symptomatic biomarkers are helpful not exclusively to distinguish patients with an infection, yet additionally to reclassify its grouping [8].

Monitoring biomarkers:

The class incorporates biomarkers that are broke down at various time focuses to screen the situation with an infection or ailment, and as a marker of the reaction to a mediation, including openness to a clinical item or a natural specialist (Figure 2) . Changes in biomarkers values are considered as signs of the movement of the clinical condition and as estimations of the pharmacological reaction and different sorts of clinical mediations . An illustration of an observing biomarker is the height of serum creatinine or potentially potassium fixations after a pharmacological or clinical intercession, boundaries that are generally utilized as a sign of the likelihood to foster incidental effects [9].

Biomarker types:

neuroimaging biomarker:

To research BPD-explicit biochemical boundaries, we looked at sex, stress chemicals, and incendiary variables among BPD and MDD patients. MDD patients introduced more significant levels of IgA ($P = 0.040$) and IgM ($P = 0.004$), while BPD patients had higher neutrophil ($P = 0.004$) and monocyte ($P = 0.002$) counts. There were no distinctions in testosterone, oestradiol, progesterone, cortisol, ACTH, CRP, C3, C4, IgG, or lymphocyte count (all $P > 0.05$) between the gatherings [10].

Peripheral biomarkers:

Dissimilar to what was found in the review included here, where the distinctions GDNF levels for patients in the euthymic state were just tracked down after amendment (Rosa et al. 2006), Barbosa et al. (2011) found higher GDNF levels in BDE contrasted with BDM patients. Different examinations don't find contrasts in that frame of mind among euthymia and HCs (Tunca et al. 2014). The irregularity of results could be because of type II mistake, and bigger example estimated investigations are required. With developing proof that aggravation adds to mental disability in a few ailments, examining this perspective in bipolar disorder is pivotal. Nonetheless, as of not long ago, the connection between fiery markers and emotional side effects isn't totally [11].

A larger number of qualities are ensnared in ASD than in some other DSM determination. Most hereditary variations are not acquired from one or the other parent however are rather again transformations. These incorporate single nucleotide variations (SNVs) and little additions or erasures (indels) that upset single quality capability, altogether involving in excess of 100 qualities to date20-23. Once more duplicate number variations (CNVs) are likewise ensnared in ASD, the vast majority of which either erase or copy numerous genes24. Arising information additionally highlight intriguing acquired SNVs and CNVs that add to ASD risk25-27. By and large, uncommon ASD-related SNVs and CNVs are seen as in around 15% of mentally unbalanced people, albeit no single variation is viewed as in over 1% [12].

Genetic markers :

As of now, the utilizations of hereditary qualities to the clinical consideration of mental patients are restricted without even a trace of explicit qualities known to be connected with mental problems, family ancestry right now goes about as an intermediary for hereditary markers and may likewise integrate at this point obscure elements connected with the ecological gamble for disease. Right now, having a family background of a problem is the best indicator of chance for improvement of a mental issue among relatives [13].

Notwithstanding fundamental purposes of family ancestry data by and by (e.g., basing prescription decisions for a patient on a treatment reaction in a family member), APA treatment rules for the administration of bipolar issue express that hereditary guiding might be useful to people with bipolar turmoil [14].

These models have been valuable in assisting with distinguishing different qualities and flagging pathways that might be associated with the improvement of burdensome side effects and, critically, in the reaction to upper medications. Here we feature a few discoveries that have created a lot of interest and animated proceeded with research in the field. Effect sizes of customary gamble factors were for the most part bigger than those of hereditary gamble factors, whether or not or not still up in the air in a free informational index. By the by, a significant variety in the impact sizes of conventional gamble factors was noticed [15].

TREATMENT OPTIONS FOR BIPOLAR DISORDER:

- Psychotherapeutic treatment
- Energizer treatment
- To distinguish and potential reuse New medications for temperament issues treatment
- Biomarkers may likewise be valuable for matching patients to drugs and estimating reaction to treatment [16].

SYMPTOMS :

- Hypomanic side effect.
- Peevishness
- Diminished need for rest.
- Trouble to concentrating and a sleeping disorder
- Self-destructive way of behaving
- Enthusiastic
- Rapture
- Uneasiness temperament [17].

THERAPY AND LIFE STYLE CHANGES

- Mental social treatment
- Family centered treatment
- MBCT care based mental treatment s
- Relational and social cadence treatment
- Peer support [18].

DIAGNOSIS:

- An emotional wellness or medical services proficient can analyze bipolar confusion utilizing measures set out in the Symptomatic and Factual Manual of Mental Issues [19].

- The NIMHTrusted Source makes sense of that for get a determination of bipolar I problem, an individual high priority experienced side effects of lunacy for something like 7 days, or less than 7 days assuming side effects were sufficiently serious to require hospitalization [20].

CAUSES FOR BIPOLAR DISORDER:

- Bipolar confusion seems to create from a blend of variables, as per the NIMHTrusted Sources [21].
- Hereditary variables: Bipolar turmoil is more normal in individuals who have a relative with the condition. A few hereditary highlights might be involved [22].

DRUGS FOR BIPOLAR DISORDER :

- Lamotrigine
- Valproate
- Olanzapine
- Quetiapine
- Aripiprazole
- Risperidone [23].

COMPLICATIONS FOR BIPOLAR DISORDER:

- Social entanglements
- Actual confusions
- Mental confusions
- Pregnancy and labor confusions
- Word related confusions [24].

FUTURE DIRECTIONS FOR BIPOLAR DISORDER:

Revelation of conceivable biomarkers for major mental problems will require a change in perspective in a biomarker disclosure approach. By and by, the field uses for the most part a conventional reductionist methodology in which center is given to the assessment of individual parts and their relationship to a mind boggling condition. Albeit this approach has upgraded how we might interpret major mental problems and aided in limiting our quest for conceivable biomarkers, it is unreasonably credulous in its capacity to give hearty biomarkers to complex peculiarities in a variety of settings [25].

CONCLUSION:

Bipolar disorder (BD) represents a significant challenge in mental health, characterized by its complex nature and the profound impact it has on individuals' lives. The differentiation between BD and depression is critical, as early recognition can prevent severe outcomes. Despite advancements in artificial intelligence and biomarker research, the field still grapples with the need for reliable diagnostic tools and effective treatment strategies. The increasing prevalence of mood disorders, exacerbated by the COVID-19 pandemic, underscores the urgency for accurate differential diagnosis and tailored interventions. Biomarkers, including neuroimaging, peripheral, and genetic markers, hold promise for enhancing our understanding of BD and

improving patient management. These biomarkers can aid in diagnosis, monitor treatment responses, and facilitate personalized therapeutic approaches. However, the current landscape reveals inconsistencies in findings and highlights the necessity for larger, more diverse studies to validate these biomarkers. Future research must pivot from traditional reductionist methods to more integrative approaches that consider the multifaceted nature of BD. By identifying robust biomarkers, we can enhance early diagnosis and treatment personalization, ultimately improving outcomes for individuals affected by this debilitating disorder. As we advance, collaboration across disciplines will be essential to translate these findings into clinical practice, ensuring that patients receive the most effective care tailored to their unique needs.

REFERENCES:

1. Dong yun lee, byungjin choi, chungsoo kim, egill fridgeirsson, jenna reps, myoungsuk kim,jiheong et.al. privacy- preserving federatedv model predicting bipolar trasition in patent with depression: prediction model development study. 01,2023; 25:
2. Nicolas salvetat, franciscos jesus checarobles, Vipul patel, Christopher cayzac, Benjamin dubuc, fabrice chimienti, jean Daniel Abraham, pierrick dupre et.al. a game changer for bipolar disorder diagnosis using rna editing- based biomarkers. 04 may 2022; 12:
3. antino c.teixeira, gabriela d, colpo,gabriel r,fries isa belle. bauer and sudhakar selvaraj. biomarkers for bipolar disorder: current status and challenges ahead . 28 nov 2018;19(1): 67-81.
4. rajesh sagar and raman deep patnayak. potential biomarkers for bipolar disorder:ehere do we stand. indian j med res.2017;145(1): 7-16.
5. strawbridge r, younge ah, cleare aj. biomarkers for depression: recent insights, current challenges and furure prospects. peer reviews. 10 may 2017; 17(13):1245-1262.
6. front psychiatry, 15 may 2020 sec. molecular psychiattry volume 11-2020.
7. Anaid perez-ramos, cristina romero-lopez-albeerca, jose i. perez- revuelta. A systematic review of the biomarkers associated with cognition and mood state in bipolar disorder. 17 may 2024; 12:
8. xiaohui jiao tong university, zhiang niu, yuncheng zhu, yifan shi. peripheral biomarkers to perdict the diagnosis of bipolar disorder from major depressive disorder in adolescents. european archives of psychiatry and clinical neuroscience. aug 2022; 272(5).
9. b.keri martinowich, robert j.schlocesser,and husseini k.manji . bipolar disorder:from genes to behavioral pathways.published april1 ,2009 volume.119, issue 4.
10. hafeman,johnmerranko,eric ayoung storm, boris birmaher,mary afristad , sarah mhorwitz,legugene arnold robert finding. generalizing prediction of bipolar disorder onset across high risk population.
11. allison g harvey, lisa s talbot,anda greshon . sleep distrubance in bipolar disorder across the lifetime.published.2012april 08
12. jenessa n johnston,ba,darcy campbell,bsc, hector j curuncho, phd ,loline d henter,ma, elizabeth d ballard,phd, carlos azarate,jr,md . suicide biomarkers to predict risk,classify diagnostic subtypes,and identify novel therapeutic targets published 02 december 2021 volume 25, issue 3,pages 197-214.
13. 1.Vieta E. Bipolar II disorder: frequent, valid, and reliable. Can. J. Psychiatry. 2019;64:541–543. doi: 10.1177/0706743719855040. [DOI] [PMC free article] [PubMed] [Google Scholar]
14. 2.Manning JS, Haykal RF, Connor PD, Akiskal HS. On the nature of depressive and anxious states in a family practice setting: the high prevalence of bipolar II and related disorders in a cohort followed longitudinally. Compr. Psychiatry. 1997;38:102–108. doi: 10.1016/s0010-440x(97)90089-4. [DOI] [PubMed] [Google Scholar]
15. 3.Ghaemi SN, Boiman E, Goodwin FK. Insight and outcome in bipolar, unipolar, and anxiety disorders. Compr. Psychiatry. 2000;41:167–171. doi: 10.1016/S0010-440X(00)90043-9. [DOI] [PubMed] [Google Scholar]
16. 4.Ghaemi SN, Soldani F, Hsu DJ. Evidence-based pharmacotherapy of bipolar disorder. Int. J. Neuropsychopharmacol. Off. Sci. J. Coll. Int. Neuropsychopharmacol. 2003;6:303–308. doi: 10.1017/S1461145703003626. [DOI] [PubMed] [Google Scholar]
17. 5.Angst J. The bipolar spectrum. Br. J. Psychiatry J. Ment. Sci. 2007;190:189–191. doi: 10.1192/bjp.bp.106.030957. [DOI] [PubMed] [Google Scholar]

18. 6.MacQueen GM, Young LT. Bipolar II disorder: symptoms, course, and response to treatment. Psychiatr. Serv. 2001;52:358–361. doi: 10.1176/appi.ps.52.3.358. [DOI] [PubMed] [Google Scholar]

19. 7.Suppes T, Hirschfeld RM, Vieta E, Raines S, Paulsson B. Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. World J. Biol. Psychiatry. 2008;9:198–211. doi: 10.1080/15622970701317265. [DOI] [PubMed] [Google Scholar]

20. 8.Bartoli F, Carra G, Clerici M. Update on bipolar disorder biomarker candidates: what about uric acid/adenosine hypothesis? Expert Rev. Mol. Diagn. 2017;17:105–106. doi: 10.1080/14737159.2017.1270757. [DOI] [PubMed] [Google Scholar]

21. 9.Teixeira AL, Salem H, Frey BN, Barbosa IG, Machado-Vieira R. Update on bipolar disorder biomarker candidates. Expert Rev. Mol. Diagn. 2016;16:1209–1220. doi: 10.1080/14737159.2016.1248413. [DOI] [PubMed] [Google Scholar]

22. 10.Menezes IC, von Werne Baes C, Lacchini R, Juruena MF. Genetic biomarkers for differential diagnosis of major depressive disorder and bipolar disorder: a systematic and critical review. Behav. Brain Res. 2019;357–358:29–38. doi: 10.1016/j.bbr.2018.01.008. [DOI] [PubMed] [Google Scholar]

23. 11.Fernandes BS, et al. The new field of 'precision psychiatry'. BMC Med. 2017;15:80. doi: 10.1186/s12916-017-0849-x. [DOI] [PMC free article] [PubMed] [Google Scholar]

24. 12.Taurines R, et al. Proteomic research in psychiatry. J. Psychopharmacol. 2011;25:151–196. doi: 10.1177/0269881109106931. [DOI] [PubMed] [Google Scholar]

25. 13.Zieske LR. A perspective on the use of iTRAQ reagent technology for protein complex and profiling studies. J. Exp. Bot. 2006;57:1501–1508. doi: 10.1093/jxb/erj168. [DOI] [PubMed] [Google Scholar]